Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping tumors: electric fields tested against pancreatic cancer

NCT ID NCT07319910

Disease control Sponsor: NovoCure GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused) This study
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This program gives adults with locally advanced pancreatic cancer access to a device that delivers gentle electric fields to the abdomen, combined with standard chemotherapy. The goal is to see if this approach is safe and feasible while the device awaits FDA approval. Participants must be able to use the device themselves or with help from a caregiver.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TTFields (electric fields) plus gemcitabine and nab-paclitaxel chemotherapy
What this could lead to
If it works, this could offer a new treatment option for people with locally advanced pancreatic cancer, potentially slowing tumor growth.
What could go wrong
This is an early access program, not a full trial, so effectiveness is not yet proven. The device requires daily wear and may cause skin irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 22 years * Histologically or cytologically confirmed de novo pancreatic adenocarcinoma * Locally advanced, non-metastatic disease * ECOG performance status of 0-2 * Candidate for treatment with gemcitabine and nab-paclitaxel * Able to operate the NovoTTF-200T system independently or with caregiver support Exclusion Criteria: * Prior palliative treatment to the pancreatic tumor * Other active malignancies within the past 5 years (except certain early-stage cancers) * Significant uncontrolled medical conditions or infections that would interfere with therapy * Implantable electronic devices in the torso * Known severe hypersensitivity to adhesives, hydrogel, or chemotherapy agents * Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced pancreatic adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced pancreatic adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.